Dr. Robert Kaida Chin, MD, PhD

Dr. Chin practices at Peter Morton UCLA Medical Building in Los Angeles, California.

Dr. Chin's NPI, 1043407992, was assigned on September 25, 2007. Dr. Chin graduated from Pritzker School of Medicine in 2006. Dr. Chin's California license number on file is A102378.

Dr. Chin's primary practice is Peter Morton UCLA Medical Building, at 200 Medical Plz, Los Angeles, CA 90024 in Los Angeles County. The practice phone is (310) 794-9206.

Dr. Chin's primary practice is Peter Morton UCLA Medical Building in Los Angeles, California. Dr. Chin is also affiliated with Ronald Reagan UCLA Medical Center. The medical group on file is UCLA Medical Group (UCLA Health). Dmand AI also links Dr. Chin to 1 more hospital, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Chin practices, 4 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Chin's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Chin is board certified in radiation oncology by the American Board of Radiology. Dmand AI has Dr. Chin's licenses on file in 4 states: California, Oregon, Washington and Illinois.

Dmand AI lists bone cancer radiation, head & neck cancer radiation, lung cancer radiation and prostate cancer radiation among the conditions Dr. Chin treats.

CMS data shows 1,664 Medicare services from Dr. Chin across 14 procedure codes in 2024, for 260 Medicare patients. Medicare paid $128,682 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 260 Medicare patients who saw Dr. Chin in 2024. The largest group is 65 to 74, with 116 patients. 75% of them have high cholesterol, and 74% have high blood pressure. 18% are also on Medicaid. Their average risk score is 2.19, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Chin's median patient age at 68, with 33% women.

In 2024, Dr. Chin wrote 33 Medicare Part D claims for 17 patients. 76% of them were for generic drugs. CMS names the drug for 11 of them, across 1 drug with 11 or more claims each, at $213 in total drug cost. In 2019, CMS named 56 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 78 out of 100 for Dr. Chin for performance year 2024, reported as part of a group. Dr. Chin accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Chin as offering telehealth.

Dmand AI links 23 papers to Dr. Chin, published from 2010 to 2022. 2016 was the busiest year, with 6. The most frequent topics are Genome, Human, Whole Genome Sequencing and Abnormalities, Multiple. Dr. Chin has published most often in Gigascience. Dr. Chin's most frequent co-authors are Amar Upadhyaya Kishan, MD, Elliot Abemayor, MD and Olujimi A. Ajijola, MD, PhD.

Dmand AI links Dr. Chin to 5 clinical trials. Conditions studied include Oropharyngeal Neoplasms, Pharyngeal Neoplasms and Tachycardia, Ventricular. Jonsson Comprehensive Cancer Center sponsors the most, 3.

CMS Open Payments shows 35 general payments to Dr. Chin from 8 drug and device companies from 2016 to 2024. Consulting fees make up the largest share, 43% of the total. Varian Medical Systems, Inc. paid the most, $18,138.

Dmand AI lists 1 award for Dr. Chin, most recently CMS Stage 1 EHR in 2013.

Dr. Chin graduated from Pritzker School of Medicine in 2006.

Dr. Chin is in network with 15 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.